|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-8-29
|
|
pubmed:abstractText |
Clinical and preclinical data indicate that tumor necrosis factor (TNF)-alpha is an important mediator of acute graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation. We completed a study using etanercept, a fusion protein capable of neutralizing TNF-alpha, for the initial treatment of aGVHD. Etanercept (25 mg subcutaneously) was administered twice weekly for 16 doses, along with methylprednisolone (2 mg/kg) and tacrolimus for biopsy-proven aGVHD. Twenty patients with a median age of 47 years (range, 8-63 years) were enrolled. Fourteen patients with grade II aGVHD (11 family donors and 3 unrelated donors) and 6 patients with grade III aGVHD (3 family donors and 3 unrelated donors) were treated. Twelve patients completed 16 doses of therapy, and 8 received 5 to 15 doses. Reasons for not completing all doses of etanercept included progression of aGVHD (n = 4), relapsed leukemia (n = 2), progression of pulmonary and central nervous system lesions (n = 1), and perforated duodenal ulcer (n = 1). Fifteen (75%) of 20 patients had complete resolution of aGVHD within 4 weeks of therapy. Increasing levels of soluble TNF receptor 1 plasma concentration during the first 4 weeks of therapy indicated progression of aGVHD in 5 patients. In contrast, for 15 responding patients, soluble TNF receptor 1 plasma concentration levels returned to baseline. These data demonstrate the feasibility of using cytokine blockade in the early treatment of aGVHD.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor...,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1083-8791
|
|
pubmed:author |
pubmed-author:AyashLoisL,
pubmed-author:BeckerMichaelM,
pubmed-author:BraunThomasT,
pubmed-author:CookeKenneth RKR,
pubmed-author:FerraraJames L MJL,
pubmed-author:HutchinsonRaymondR,
pubmed-author:JonesDawnD,
pubmed-author:LevineJohn EJE,
pubmed-author:RatanatharathornVoravitV,
pubmed-author:ReynoldsChristopherC,
pubmed-author:RoenP BPB,
pubmed-author:SilverSamuelS,
pubmed-author:UbertiJoseph PJP,
pubmed-author:WhitfieldJoelJ,
pubmed-author:YanikGregoryG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
680-7
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16125638-Adolescent,
pubmed-meshheading:16125638-Adult,
pubmed-meshheading:16125638-Anti-Inflammatory Agents,
pubmed-meshheading:16125638-Bone Marrow Transplantation,
pubmed-meshheading:16125638-Child,
pubmed-meshheading:16125638-Drug Therapy, Combination,
pubmed-meshheading:16125638-Female,
pubmed-meshheading:16125638-Graft vs Host Disease,
pubmed-meshheading:16125638-Humans,
pubmed-meshheading:16125638-Immunoglobulin G,
pubmed-meshheading:16125638-Immunosuppressive Agents,
pubmed-meshheading:16125638-Lymphoproliferative Disorders,
pubmed-meshheading:16125638-Male,
pubmed-meshheading:16125638-Methylprednisolone,
pubmed-meshheading:16125638-Middle Aged,
pubmed-meshheading:16125638-Pilot Projects,
pubmed-meshheading:16125638-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:16125638-Receptors, Tumor Necrosis Factor, Type I,
pubmed-meshheading:16125638-Tacrolimus,
pubmed-meshheading:16125638-Transplantation, Homologous,
pubmed-meshheading:16125638-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.
|
|
pubmed:affiliation |
Department of Internal Medicine, Blood and Marrow Stem Cell Transplantation Program, University of Michigan, Ann Arbor, USA. ubertij@karmanos.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, N.I.H., Extramural
|
